• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

    183.33 -2.85 (-1.53%)
    Streaming Delayed Price Updated: 2:05 PM EST, Feb 20, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 265,981
    Open 186.00
    Bid (Size) 183.18 (100)
    Ask (Size) 183.48 (100)
    Prev. Close 186.18
    Today's Range 181.83 - 186.00
    52wk Range 86.99 - 191.50
    Shares Outstanding 47,190,970
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Axsome Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Alkem Laboratories Ltd.
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +2.6%
    +2.6%
    1 Month
    -0.6%
    -0.6%
    3 Month
    +27.9%
    +27.9%
    6 Month
    +56.5%
    +56.5%
    1 Year
    +44.4%
    +44.4%

    More News

    Read More
    News headline image
    Should You Buy Axsome Therapeutics Stock Before Feb. 23? ↗
    Via The Motley Fool
    News headline image
    1 High-Flying Stock With More Upside Ahead ↗
    Via The Motley Fool
    Topics Intellectual Property
    AXSOME THERAPEUTICS INC (NASDAQ:AXSM) Fits the Minervini Growth Momentum Strategy ↗
    Via Chartmill
    News headline image
    Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    The Great Rotation: Russell 2000’s Historic 15-Day Streak Marks a Seismic Shift in Market Leadership
    Via MarketMinute
    Topics Artificial Intelligence ETFs Economy
    News headline image
    AXSM Stock Rises After Analyst Hikes Price Target On Auvelity Drug Optimism ↗
    Via Stocktwits
    Topics Artificial Intelligence
    News headline image
    Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out ↗
    Via MarketBeat
    News headline image
    2 Healthcare Stocks to Buy for 2026 and Beyond ↗
    Via The Motley Fool
    News headline image
    Regencell Bioscience (RGC) Stumbles into 2026: 8% Year-End Slide Sparks Technical Caution
    Via MarketMinute
    Here are the top movers in Wednesday's session. ↗
    Via Chartmill
    News headline image
    Why Axsome Therapeutics Stock Rocketed Higher to End 2025 ↗
    Via The Motley Fool
    The market is filled with gapping stocks in Wednesday's session. ↗
    Via Chartmill
    News headline image
    Axsome Advances Toward FDA Filing For Drug To Treat Narcolepsy ↗
    Via Stocktwits
    News headline image
    Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer’s Disease Agitation
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    2 Under-the-Radar Stocks to Buy Heading Into 2026 ↗
    Via The Motley Fool
    News headline image
    Beyond AI: How Non-AI Tech Innovations are Fueling a New Era of Stock Market Growth
    Via MarketMinute
    Topics Artificial Intelligence Economy Emissions
    News headline image
    Axsome (AXSM) Q3 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Axsome Therapeutics to Participate in Upcoming Investor Conferences
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Pomerantz LLP and The Rosen Law Firm, P.A. Announce Proposed Class Action Settlement on Behalf of Purchasers of Axsome Therapeutics, Inc. Common Stock - AXSM
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    2 Monster Stocks in the Making ↗
    Via The Motley Fool

    Frequently Asked Questions

    Is Axsome Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Axsome Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Axsome Therapeutics, Inc. - Common Stock trade on?
    Axsome Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Axsome Therapeutics, Inc. - Common Stock?
    The ticker symbol for Axsome Therapeutics, Inc. - Common Stock is AXSM on the Nasdaq Stock Market
    What is the current price of Axsome Therapeutics, Inc. - Common Stock?
    The current price of Axsome Therapeutics, Inc. - Common Stock is 183.33
    When was Axsome Therapeutics, Inc. - Common Stock last traded?
    The last trade of Axsome Therapeutics, Inc. - Common Stock was at 02/20/26 02:05 PM ET
    What is the market capitalization of Axsome Therapeutics, Inc. - Common Stock?
    The market capitalization of Axsome Therapeutics, Inc. - Common Stock is 8.65B
    How many shares of Axsome Therapeutics, Inc. - Common Stock are outstanding?
    Axsome Therapeutics, Inc. - Common Stock has 9B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.